{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
amphotericin b
to a specific field?
Status:
Investigational
Source:
NCT03784378: Phase 1 Interventional Completed Non Small Cell Lung Cancer
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
CEP-32496 (RXDX 105) is an orally administered, small molecule, VEGFRsparing, RET, BRAF, EGFR tyrosine kinase inhibitor, for the treatment of solid tumours, including malignant melanoma and colorectal cancer. CEP-32496 was originally discovered by Ambit Biosciences (now Daiichi Sankyo) and Cephalon (now owned by Teva) as part of a research programme to develop orally administered kinase inhibitors. The worldwide rights to the compound were licensed to Teva by Ambit, following the acquisition of Cephalon by Teva. Teva, in March 2015, entered into an asset purchase agreement with Ignyta, pursuant to which, Ignyta has acquired worldwide rights and assets of four oncology development programmes, including CEP-32496. Following the acquisition of the compound by Ignyta, CEP 32496 has been renamed to RXDX 105. Phase I/Ib development of RXDX 105 for the treatment of advanced solid tumours is underway in the US.
Class (Stereo):
CHEMICAL (ACHIRAL)
Benzethidine an opioid analgesic that was forbidden for use.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Betaprodine is an opioid analgesic under international control according to the UN Single Convention 1961. It has been used in obstetrics, as pre-operative medication, for minor surgical procedures.
Status:
Investigational
Source:
INN:carvotroline [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Carvotroline [WY 47791] is a novel γ-carboline derivative with a preclinical profile suggestive of antipsychotic activity. Carvotroline has an affinity for the dopamine D2 receptor and cortical 5-HT2 receptor that is ten times greater than serotonin. Carvotroline administration to rats leads to a decrease of plasma corticosterone levels and demonstrated a moderating effect on the rotational-stress induced rise in plasma corticosterone levels.
Status:
Investigational
Source:
INN:edaglitazone [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Edaglitazone have a clear PPAR-gamma agonist profile, with predominant PPAR-gamma activity and little PPAR-alpha activity. Edaglitazone was reported to significantly improve insulin sensitivity and enhance the rate of glucose oxidation in both the presence and absence of insulin. Additional studies have shown that edaglitazone affects muscle glucose metabolism by additional mechanisms other than PPAR-gamma activation. Phase I clinical studies have revealed that edaglitazone is well-tolerated and capable of significantly improving glucose homeostasis. Edaglitazone had been in phase II clinical trials for the treatment if type 2 diabetes. However, this research has been discontinued.
Status:
Investigational
Source:
NCT00257621: Phase 2 Interventional Completed Infection, Human Immunodeficiency Virus I
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Brecanavir (previously known as VX-385), a HIV aspartyl protease inhibitor was developed for the treatment of HIV. The inhibition of HIV viral proteinase enzyme prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. Brecanavir reached Phase II development. However, GlaxoSmithKline announced to discontinue development brecanavir. Because of the inability to develop a viable oral dosage formulation capable of delivering the desired brecanavir levels in patients with multi-drug resistant HIV.
Status:
Investigational
Source:
NCT00671073: Phase 2 Interventional Completed Pulmonary Disease, Chronic Obstructive
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Oglemilast (GRC-3886), is a potent and selective PDE4 inhibitor (IC50: 2.5 nM (PDE4B) and 1.7 nM (PDE4D)). Oglemilast is in phase II clinical trials for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Oglemilast was originally developed by Glenmark Pharmaceuticals, and licensed to Forest (acquired by Actavis in 2014) for the rights in North America in 2004. Teijin Pharma obtained the rights of the compound in Japan in 2005.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Feloprentan is an endothelin receptor antagonist.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cefuracetime is an impurity of Cefuroxime, which is an antibacterial agent.
Status:
Investigational
Source:
INN:diampromide [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Diampromide is a synthetic narcotic analgesic. It was designed as a methadone analog and hence with a chiral center similar to that of the parent. Diampromide approximates to the potency of pethidine and morphine in mice and rats, respectively. It has been evaluated in postoperative pain. Diampromide is not found in any pharmaceutical preparations sold in the United States. It is under international control according to the UN Single Convention 1961 and its amendments, Schedule I.
